Patent Expiry

Patent/Exclusivity Expiry: ITOVEBI

Other upcoming events for RGNX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Ped

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: ITOVEBI — RGNX Patent Expiry | BioSniper